Risk Partners Life Sciences Roundtable 2025, thank you very much! 

Contact us

We congratulate Steyr Motors AG on the successful listing
in the Scale Segment of the German Stock Exchange on October 30, 2024!

Risk Partners had the honor to act as IPO underwriting counsel in this transaction. Our team, led by Florian Eckstein and Björn Stressenreuter, supported Steyr Motors AG in its IPO on the Frankfurt Stock Exchange. Our expertise and comprehensive support were geared towards providing Steyr Motors with a secure and successful start on the capital markets.

We would like to thank Julian Cassutti and Christoph Cerar from Steyr Motors and the team at Mutares SE & Co. KGaA for the successful cooperation and their trust in our expertise.

With this step, Steyr Motors AG has not only gained access to additional capital for further growth, but has also strengthened its position as an innovation leader in the field of engine technology. 

About the Scale Segment of Deutsche Börse

Deutsche Börse's Scale segment offers small and medium-sized companies more straightforward access to the capital market and facilitates the financing of innovation and growth projects. Companies in the Scale segment benefit from a standardized listing process and special advisory networks that help them to master the challenges of the capital market with confidence.

At Risk Partners, we pride ourselves on supporting companies like Steyr Motors AG with specialized insurance solutions and comprehensive advice. From management liability insurance to innovative insurance products specifically tailored to the challenges and opportunities of an IPO, we offer customized solutions for our clients. When going public on a German stock exchange or through our innovative public flip concept when going public on a foreign stock exchange.

Ready for the next step?

For companies that are also looking to go public, Risk Partners offers tailor-made insurance solutions and advice to make this step a safe one. Contact us to find out how we can support you on your journey to the stock market.

Also read our other blog posts

Management

Research breakdown at Stockholm's Karolinska Institute: A cooling failure destroys cell cultures from decades of research

Research mishap at Stockholm's Karolinska Institute: A cooling failure destroys cell cultures from decades of research - can you insure against it? An incident that threatens your very existence, but which we would like to shed some light on from the perspective of an insurance broker specializing in life sciences. What happened? A cooling system at the Karolinska Institute in Stockholm, Sweden's most important medical research center, failed for five days. Biological material that had been collected over 30 years and, according to the institute, was unique in the world, was destroyed as a result. The material was stored in deep-freeze tanks in which the temperature

Read more "
June 7, 2024
Life Sciences

Finance Day 2023

Growth capital for biotechnology: Yesterday, today, tomorrow! A few days ago, Jutta Zaglauer and Florian Eckstein from our team attended the Finance Day 2023 on the occasion of the 25th anniversary of biotechnology at the IZB - Innovation and Startup Center for Biotechnology. The event offered an exciting exchange and insights into current financing and capital market issues of biotechnology companies. As an experienced specialist insurance broker for the areas of life sciences, venture capital and IPOs, all three cornerstones of our "magic expertise triangle" were part of the exciting agenda. It was also interesting to discuss the importance of customized

Read more "
November 6, 2023
Being Public

Risk Partners supports successful uplisting of Formycon AG to the Prime Standard

Congratulations to Formycon AG on its successful uplisting to the Prime Standard of Deutsche Börse on November 12, 2024! Welcome to the Prime Standard league: A new champion of life sciences and biosimilars has successfully made the step from the Scale segment. We proudly congratulate Enno Spillner, Dr. Caroline Redeker, Daniel Marquard and the entire Formycon AG team on this great success and another important milestone on their way to becoming a global champion in the field of biosimilars! Formycon AG has focused on

Read more "
November 14, 2024
Life Sciences

Cyber Risks: Case Study Evotec

Last year, more than 10 percent of German companies were affected by an IT security incident, with the proportion rising due to cyber attacks. Biotechnology is not excluded either. It is possible to learn from the Evotec case. It is about successful cyber attacks or other incidents that are important for security, such as acts of sabotage or hardware theft. According to a representative Ipsos survey conducted on behalf of the TÜV association among 501 companies with more than ten employees. According to the TÜV

Read more "
October 22, 2023
Cyber Security

"Digital Operational Resilience Act" (DORA regulation) from the perspective of venture capital and private equity funds

DORA regulation applies from January 2025. Significance for our private equity and venture capital clients The somewhat unwieldy name "Digital Operational Resilience Act" (DORA for short) has a very serious background and is fundamentally to be welcomed. After all, when we evaluate our claims in the context of cybercrime, PE and VC funds and their KVGs are those with the highest frequency of claims. It can be safely assumed that they are a "worthwhile target group" for cyber criminals based abroad.

Read more "
December 27, 2024
Life Sciences

St. Gallen study: USD 6 billion per drug

HSG St. Gallen: Drug costs USD 6.16 billion on average. Are the days of new drugs costing less than USD 1 billion over? There were figures in the industry that spoke of USD 700-1,000 million as the cost of developing a new drug. A study by the University of St. Gallen covering the period 2001-2020 found that the cost of developing new drugs has risen dramatically. It was estimated that the cost of developing a new drug now stands at

Read more "
September 26, 2023